Kamada (NASDAQ:KMDA – Get Free Report) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.
Several other analysts have also weighed in on KMDA. Stifel Nicolaus started coverage on Kamada in a report on Wednesday, July 3rd. They set a “buy” rating and a $18.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Kamada in a research note on Thursday, August 15th.
View Our Latest Stock Report on Kamada
Kamada Stock Performance
Institutional Investors Weigh In On Kamada
Large investors have recently modified their holdings of the stock. Calton & Associates Inc. acquired a new stake in Kamada in the 4th quarter valued at $111,000. Y.D. More Investments Ltd lifted its holdings in shares of Kamada by 107.1% during the fourth quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after acquiring an additional 15,000 shares during the period. Aristides Capital LLC lifted its holdings in shares of Kamada by 41.6% during the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after acquiring an additional 16,635 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after purchasing an additional 100,800 shares in the last quarter. 20.38% of the stock is currently owned by institutional investors.
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Featured Stories
- Five stocks we like better than Kamada
- What is a Death Cross in Stocks?
- BHP Stock: The Under-the-Radar Growth Story in Commodities
- ESG Stocks, What Investors Should Know
- Analysts Upgrade These 3 Hot Buy-and-Hold Stocks
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Kohl’s Charts a Resilient Path in a Challenging Retail Landscape
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.